Maze Therapeutics (NASDAQ:MAZE) Raised to Strong-Buy at TD Cowen

Key Points

• TD Cowen upgraded Maze Therapeutics to “strong buy,” while analysts overall maintain a “Buy” consensus with an average price target of $66.00.
• Maze shares opened at $29.60, with a market capitalization of approximately $1.64 billion; the company met estimates with a quarterly loss of $0.76 per share.
• Insiders sold 108,110 shares worth roughly $3.06 million over the past 90 days, while several institutional investors—including Alphabet—established or increased positions.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) was upgraded by analysts at TD Cowen to a "strong-buy" rating in a note issued to investors on Monday,Zacks.com reports.

A number of other analysts also recently issued reports on MAZE. Wall Street Zen downgraded Maze Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, August 15th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Maze Therapeutics in a research report on Wednesday, June 24th. Finally, BTIG Research reiterated a "buy" rating and set a $46.00 price target on shares of Maze Therapeutics in a research note on Wednesday, August 12th. Three investment analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Buy" and an average price target of $66.00.

Maze Therapeutics Stock Up 0.6%

Maze Therapeutics stock opened at $29.60 on Monday. Maze Therapeutics has a twelve month low of $12.91 and a twelve month high of $53.65. The firm has a 50 day moving average price of $28.42 and a 200-day moving average price of $32.27. The company has a market capitalization of $1.64 billion, a P/E ratio of -11.75 and a beta of 2.22. The company has a quick ratio of 18.31, a current ratio of 18.31 and a debt-to-equity ratio of 0.09.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.76). As a group, equities analysts predict that Maze Therapeutics will post -2.72 EPS for the current year.

Insider Activity

In related news, insider Atul Dandekar sold 7,500 shares of the business's stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $27.34, for a total transaction of $205,050.00. Following the completion of the transaction, the insider owned 26,250 shares of the company's stock, valued at approximately $717,675. The trade was a 22.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CMO Harold Bernstein sold 16,142 shares of the business's stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $27.61, for a total transaction of $445,680.62. Following the transaction, the chief marketing officer directly owned 16,142 shares of the company's stock, valued at approximately $445,680.62. This represents a 50.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 108,110 shares of company stock worth $3,057,531. 5.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Alphabet Inc. bought a new stake in shares of Maze Therapeutics during the 2nd quarter valued at about $41,435,000. TRV GP IV LLC bought a new position in shares of Maze Therapeutics in the second quarter worth approximately $133,502,907,000. Spruce Street Capital LP bought a new position in shares of Maze Therapeutics in the first quarter worth approximately $5,970,000. Boothbay Fund Management LLC raised its stake in Maze Therapeutics by 16.3% in the fourth quarter. Boothbay Fund Management LLC now owns 409,372 shares of the company's stock valued at $16,960,000 after purchasing an additional 57,497 shares in the last quarter. Finally, Walleye Capital LLC purchased a new stake in Maze Therapeutics in the second quarter valued at approximately $3,820,000.

About Maze Therapeutics

Maze Therapeutics, Inc NASDAQ: MAZE is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze's approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source